Hep C Cost-Effectiveness Study Supports Limiting Incivek Use
This article was originally published in The Pink Sheet Daily
Study presented at AASLD provides evidence of the potential value of genotyping patients prior to treatment with new protease inhibitors; Medco ready to start testing program.
You may also be interested in...
Most market analysts predicted Vertex's protease inhibitor would be a bigger seller than Merck's, but a greater than 10-to-1 disparity in third-quarter net sales is still eye-opening.
Vertex Pharmaceuticals' Incivek (telaprevir) has cleared FDA with labeling advantages that should enable it to win a majority of patients in the battle against Merck's competing protease inhibitor for hepatitis C, Victrelis (boceprevir).
Pharmacy benefits management company Medco Health Solutions Inc. says that with the newly approved oral anticoagulant Pradaxa (dabigatran) off to a good commercial start, it plans to monitor outcomes and compare results with generic warfarin that has been optimized according to genetic testing.